within Pharmacolibrary.Drugs.S_SensoryOrgans.S01E_AntiglaucomaPreparationsAndMiotics.S01EX01_Guanethidine;

model Guanethidine
  extends Pharmacolibrary.Drugs.ATC.S.S01EX01;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>S01EX01</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Guanethidine is a sympatholytic antihypertensive agent that blocks the release of norepinephrine from sympathetic nerve endings. It was primarily used to treat moderate to severe hypertension, but its clinical use has largely been discontinued due to the availability of better-tolerated antihypertensive medications.</p><h4>Pharmacokinetics</h4><p>Estimated pharmacokinetics for healthy adult individuals, as no published data available.</p><h4>References</h4><ol><li><p>McAllister, RG (1975). Guanethidine in antihypertensive therapy: experience with an oral loading regimen. <i>Journal of clinical pharmacology</i> 15(11-12) 771–778. DOI:<a href=\"https://doi.org/10.1002/j.1552-4604.1975.tb02341.x\">10.1002/j.1552-4604.1975.tb02341.x</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/1104667/\">https://pubmed.ncbi.nlm.nih.gov/1104667</a></p></li><li><p>Smith, DF, &amp; Shimizu, M (1978). The role of plasma volume, plasma renin and the sympathetic nervous system in the posture-induced decline in renal lithium clearance in man. <i>Neuropsychobiology</i> 4(6) 328–332. DOI:<a href=\"https://doi.org/10.1159/000117648\">10.1159/000117648</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/692834/\">https://pubmed.ncbi.nlm.nih.gov/692834</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end Guanethidine;
